The Report Covers United States Blood Glucose Monitoring Market Outlook and it is segmented into Type (Self-monitoring Blood Glucose Devices and Continuous Glucose Monitoring Devices) and Components (Glucometer Devices, Test Strips, Lancets, Sensors, and Durables). The report offers the value (in USD million) and volume (in unit million) for the above segments.

The Report Covers Spain Blood Glucose Monitoring Market Companies and it is segmented into Type (Self-monitoring Blood Glucose, and Continuous Glucose Monitoring), Component (Glucometer Devices, Test Strips, Lancets, Sensors, and Durables). The report offers the value (in USD million) and volume (in Units million) for the above segments.

The global continuous glucose monitoring device market is estimated to be valued at USD 12,690.7 million in 2025 and is projected to reach USD 54,553.1 million by 2035, registering a CAGR of 15.7% over the forecast period.

Metric	Value
Industry Size (2025E)	USD 12,690.7 million
Industry Value (2035F)	USD 54,553.1 million
CAGR (2025 to 2035)	15.7%

Country Wise Outlook

Country	CAGR (2025 to 2035)
USA	12.6%

Country	CAGR (2025 to 2035)
UK	12.7%

Region	CAGR (2025 to 2035)
European Union	12.9%

Country	CAGR (2025 to 2035)
Japan	12.4%

Country	CAGR (2025 to 2035)
South Korea	12.6%

The global blood glucose monitoring devices market size was valued at around USD 19.71 billion in 2025 and is projected to grow at a CAGR of more than 8.2%, reaching USD 43.35 billion revenue by 2035, impelled by the increase in the number of patients with type-1 or insulin-dependent type-2 diabetes.

Self-monitoring Blood Glucose Market was valued at USD 10.28 Billion in 2024 and is expected to reach USD 16.87 billion by 2030 with a CAGR of 8.61%.

Pages	188
Market Size	2024: USD 10.28 Billion
Forecast Market Size	2030: USD 16.87 Billion
CAGR	2025-2030: 8.61%
Fastest Growing Segment	Type 2 Diabetes
Largest Market	North America
Key Players	1. Abbott Laboratories 2. Medtronic plc 3. F. Hoffmann-La Roche Ltd 4. Ascensia Diabetes Care 5. Dexcom, Inc. 6. Sanofi 7. Novo Nordisk 8. Insulet Corporation 9. Ypsomed Holdings 10. Glysens Incorporated

The Europe Blood Glucose Monitoring Market Report is Segmented by Device Type (Self-Monitoring Blood Glucose Devices [Glucometer Devices, Test Strips, and Lancets] and Continuous Glucose Monitoring Devices [Sensors and Durables]), End User (Home Healthcare, Hospitals & Clinics, and Pharmacies & Others), and Geography (Germany, France, United Kingdom, Italy, Spain and More). The Market Forecasts are Provided in Terms of Value (USD).

Explore insights from Market Research Intellect's Continuous Blood Glucose Monitoring Market Report, valued at 5.3 billion USD in 2024, expected to reach 10.2 billion USD by 2033 with a CAGR of 8.5% during 2026-2033.Uncover opportunities across demand patterns, technological innovations, and market leaders.

The Germany Blood Glucose Monitoring Market is Segmented Into Type (Self-Monitoring Blood Glucose Devices and Continuous Glucose Monitoring Devices), Component (Glucometer Devices, Test Strips, Lancets, Sensors, and Durables). The Market Provides the Value (in USD) for the Above-Mentioned Segments.

The global continuous blood glucose monitoring market size is projected to grow from USD 8.35 billion in 2025 to USD 21.12 billion by 2033, exhibiting a CAGR of 12.3%.
Report Scope:

Report Metric	Details
Market Size in 2024	USD 7.44 Billion
Market Size in 2025	USD 8.35 Billion
Market Size in 2033	USD 21.12 Billion
CAGR	12.3% (2025-2033)
Base Year for Estimation	2024
Historical Data	2021-2023
Forecast Period	2025-2033
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered	By Product,By End-User,By Region.
Geographies Covered	North America, Europe, APAC, Middle East and Africa, LATAM,
Countries Covered	U.S., Canada, U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux, China, Korea, Japan, India, Australia, Taiwan, South East Asia, UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Brazil, Mexico, Argentina, Chile, Colombia,

According to Cognitive Market Research, the global Continuous glucose monitoring market size will be USD 4751.6 million in 2025. It will expand at a compound annual growth rate (CAGR) of 8.00% from 2025 to 2033.

North America held the major market share for more than 40% of the global revenue with a market size of USD 1758.09 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1377.96 million.
APAC held a market share of around 23% of the global revenue with a market size of USD 1140.38 million in 2025 and will grow at a compound annual growth rate (CAGR) of 10.8% from 2025 to 2033.
South America has a market share of more than 5% of the global revenue with a market size of USD 180.56 million in 2025 and will grow at a compound annual growth rate (CAGR) of 8.7% from 2025 to 2033.
The Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 190.06 million in 2025 and will grow at a compound annual growth rate (CAGR) of 9.3% from 2025 to 2033.
Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 104.54 million in 2025 and will grow at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2033.
Dexcom G4 Platinum is the fastest growing category of the Continuous glucose monitoring industry

Market Dynamics of Continuous glucose monitoring Market

Key Drivers for Continuous glucose monitoring Market

Increasing Incidence Of Diabetes Boost Market Growth

The rising prevalence of diabetes will drive market expansion. Chronic diabetes is caused by either insufficient insulin production by the pancreas or the body's inability to use the insulin it produces. According to the International Diabetes Federation's (IDF) Diabetes Atlas Tenth Edition 2021, diabetes affects approximately 537 million adults aged 20 to 79 years. By 2030, there will be 643 million diabetics in the world and 783 million by 2045. Nearly one in every two (240 million) adults with diabetes go undiagnosed, with three out of four living in low- and middle-income countries. Diabetes killed 6.7 million people and cost the healthcare system at least $966 billion, or 9% of total adult spending. Type 1 diabetes affects more than 1.2 million children and adolescents aged 0 to 19. Diabetes affects one of every six live births (21 million). Five hundred forty-one million adults are at higher risk of developing type II diabetes. As a result, the increasing prevalence of diabetes will drive market growth

https://idf.org/about-diabetes/diabetes-facts-figures/

Healthcare Infrastructure Development Drives Market Growth

The growth of healthcare infrastructure and rising healthcare expenditures contribute to the advancement of the market. In developed countries, the average yearly healthcare costs associated with diabetes are about $16,752 per individual. Research has indicated that the adoption of continuous glucose monitoring (CGM) systems can lead to a 25% reduction in hospital admissions and a 30% decrease in emergency room visits among consistent users, highlighting the considerable cost-saving opportunities in managing diabetes. For example, in 2023, UnitedHealthcare, a prominent health insurance provider in the U.S., started offering coverage for continuous glucose monitors for individuals with type 2 diabetes who need insulin, thereby making this technology more accessible to a wider range of patients.

Restraint Factor for the Continuous glucose monitoring Market

High Cost Related to Devices, Will Limit Market Growth

The high cost of continuous glucose monitoring systems is likely to have a negative impact on the market's early development. In developing countries such as India, patients bear the cost of blood glucose monitors and testing strips. Continuous glucose monitors are more expensive than finger-prick blood glucose testing; on average, a starter kit with replaceable sensors costs $1,000. Some CGM systems can cost several thousand dollars annually. The Dexcom G6, a popular CGM, has an average annual retail price of around $6,000, or $500 per month

Limiting Accessibility for Patients Without Comprehensive Health Insurance Coverage hamper the market

Limited access to patients who do not have complete health insurance coverage is a major limi...

Blood Glucose Monitoring Market valued at USD 20.81 Bn in 2025, is anticipated to reaching USD 41.63 Bn by 2032, with a steady annual growth rate of 10.4% .

The size of the North America Blood Glucose Monitoring Market market was valued at USD 15.51 Million in 2023 and is projected to reach USD 36.78 Million by 2032, with an expected CAGR of 13.13% during the forecast period. Recent developments include: March 2023: Modified Abbott CGM sensors scored FDA nod for use in automated insulin delivery systems., December 2022: Dexcom, a company that manufactures continuous glucose monitors (CGMs) for blood sugar management, announced the FDA approval for their next-generation product, the Dexcom G7 CGM. The G7 is approved for people with all types of diabetes from ages two years and older.. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: Continuous Glucose Monitoring Holds Highest Market Share in the North American Blood Glucose Monitoring Market..

As the world continues to face diabetes burden, accurate and efficient glucose monitoring becomes paramount for managing this condition. Courtesy of this, global demand for glucose monitoring devices is anticipated to surge at 10.6% CAGR during the next decade.

Attributes	Key Insights
Market Value in 2023	US$ 14.7 billion
Market Revenue in 2024	US$ 16.2 billion
Global Glucose Monitoring Device Market Size in 2034	US$ 44.6 billion
Value CAGR (2024 to 2034)	10.6%

Country-wise Insights

Countries	Value CAGR
United States	6.1%
China	16.6%
Japan	4.0%
Germany	6.7%
India	17.6%

Category-wise Insights

Product	Value CAGR
Continuous Monitoring Devices	14.7%
Self-monitoring Devices	6.7%

Indication	Value CAGR
Diabetes Type I	6.2%
Diabetes Type II	12.3%
Gestational Diabetes	2.7%

Blood Glucose Monitoring Device Market surges at 8.1% CAGR, rising from USD 14.40 billion in 2024 to USD 31.31 billion by 2034, get powerful data on wearable sensors & remote patient care.

The global blood glucose monitoring (BGM) market, valued at $2.98 billion in 2025, is projected to experience robust growth, driven by rising prevalence of diabetes, an aging global population, and increasing adoption of continuous glucose monitoring (CGM) systems. The market's compound annual growth rate (CAGR) of 8.5% from 2025 to 2033 indicates significant expansion opportunities. Key drivers include the convenience and improved health outcomes associated with CGM, growing awareness of diabetes management, and technological advancements leading to smaller, more accurate, and user-friendly devices. Furthermore, the increasing availability of affordable BGM devices in emerging economies is fueling market growth. However, the market faces restraints such as the high cost of CGM systems, particularly in low- and middle-income countries, and potential inaccuracies in some self-monitoring blood glucose (SMBG) devices. The market is segmented into SMBG, CGM, and lancets, with CGM experiencing the fastest growth due to its continuous data provision enabling proactive diabetes management. Leading companies like Abbott Laboratories, Dexcom Inc., and Medtronic Plc are aggressively pursuing market share through product innovation, strategic partnerships, and expansions into new geographic markets. Competitive strategies focus on technological advancements, improved accuracy, data integration with mobile applications, and development of user-friendly interfaces. Industry risks include stringent regulatory approvals, intense competition, and potential cybersecurity concerns related to data privacy in connected devices. The regional distribution of the market reflects varying levels of diabetes prevalence and healthcare infrastructure. North America currently holds a significant market share due to high diabetes prevalence and advanced healthcare systems. However, the Asia-Pacific region is expected to witness considerable growth in the forecast period driven by rising diabetes rates in countries like India and China, coupled with increasing disposable incomes and improved healthcare access. Europe and other developed regions will maintain steady growth, primarily driven by technological upgrades and increased adoption of sophisticated monitoring systems. The competitive landscape is characterized by both established players and emerging companies offering innovative solutions. Successful companies will continue to focus on enhancing the accuracy and ease of use of their devices while emphasizing data-driven insights for better patient outcomes.

Snapshot img

Blood Glucose Monitoring Devices Market Size 2025-2029

The blood glucose monitoring devices market size is forecast to increase by USD 10.14 billion at a CAGR of 10% between 2024 and 2029.

The market is experiencing significant growth, driven by the rising global burden of diabetes and the increasing adoption of advanced technologies such as smart watch-based apps for continuous glucose monitoring. According to the International Diabetes Foundation, approximately 463 million adults were living with diabetes in 2019, and this number is projected to reach 700 million by 2045. This growing population of diabetes patients presents a substantial market opportunity for blood glucose monitoring device manufacturers. However, the market faces challenges that could hinder its growth potential. Regulatory hurdles impact adoption, as these devices must meet stringent regulatory requirements to ensure accuracy and safety.
Additionally, supply chain inconsistencies can pose challenges, as the demand for these devices is often volatile and requires a reliable and flexible supply chain to meet patient needs effectively. To capitalize on market opportunities and navigate these challenges, companies must focus on regulatory compliance, supply chain optimization, and the development of user-friendly and accurate devices that meet the evolving needs of diabetes patients. Technological advances in this field have led to more sophisticated devices, such as continuous glucose monitoring systems, insulin syringe and pens, which offer enhanced functionality and improved patient outcomes. The hospital end-use segment supports inpatient monitoring, while home healthcare segment devices empower individuals with convenient glucose monitoring solutions. By addressing these challenges, market participants can position themselves for long-term success in the market.

What will be the Size of the Blood Glucose Monitoring Devices Market during the forecast period?

Request Free Sample

The market is experiencing significant growth, driven by the increasing prevalence of diabetes and the demand for advanced technologies to support personalized diabetes management. Patient engagement is a key trend, with diabetes prevention programs emphasizing diet and exercise, and digital health solutions enabling remote patient monitoring through the Internet of Things. Artificial intelligence and machine learning are revolutionizing data analytics, enabling early detection of diabetes complications and improving quality of life through data interpretation. Diabetes research continues to advance, with innovation in sensor calibration and cloud computing enhancing the accuracy and accessibility of blood glucose monitoring.
The market encompasses a range of essential tools including glucose meters, lancets, and test strips, crucial for managing conditions like Type 2 diabetes. Innovations like Insulin pumps and Continuous Glucose Monitoring (CGM) systems such as Eversense CGM utilize advanced sensor technologies and microminiaturization. Diabetes awareness and education programs are also crucial, leveraging digital platforms to reach larger audiences and promote lifestyle modifications. Overall, the market is dynamic and innovative, with a focus on improving diabetes management and preventing complications.

How is this Blood Glucose Monitoring Devices Industry segmented?

The blood glucose monitoring devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

End-user

  Hospitals
  Home care
  Diagnostic centers


Product

  SMBG
  CGM
  Lancets


Indication

  Type-2 diabetes population
  Type-1 diabetes population


Geography

  North America

    US
    Canada
    Mexico


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  Rest of World (ROW)

By End-user Insights

The hospitals segment is estimated to witness significant growth during the forecast period.

The diabetes care market encompasses various devices and technologies used for managing diabetes, with blood glucose monitoring devices being a crucial component. These devices include blood glucose meters, continuous glucose monitoring systems like Guardian Connect and Dexcom G6, and non-invasive glucose monitoring solutions. Diabetes educators and primary care physicians often recommend these tools for individuals with diabetes, including those with type 1, type 2, and gestational diabetes. Blood glucose meters provide instant readings, while continuous glucose monitoring systems offer real-time data logging and predictive capabilities. Wearable technology, such as insulin pumps and flash glucose monitoring systems like the Freestyle Libre, enable remote monitoring and data analysis.

Clo

Explore the continuous glucose monitoring device market valued at $ 5.17 billion in 2024 & expected to reach USD 10.15 billion by 2034 growing at a CAGR of 7%

The size of the Blood Glucose Monitoring Market was valued at USD 18.81 billion in 2023 and is projected to reach USD 32.98 billion by 2032, with an expected CAGR of 8.35% during the forecast period. Recent developments include: June 2022: Abbott announced that it's developing a new bio-wearable that will continuously monitor glucose and ketone levels in one sensor. The system has secured breakthrough device designation from the U.S. Food and Drug Administration, which is designed to expedite the review of innovative technologies that can improve the lives of people with life-threatening or irreversibly debilitating diseases or conditions., May 2021: Roche Diabetes Care Canada announces a collaboration with Ellerca Health, for improving patient care through innovation and technology. The partnership will include the launch of Accu-Chek and 360Care, combining Roche's Accu-Chek Guide blood glucose meter, customized home delivery of testing strips, and Ellerca's self-management digital program, 360Care, which empowers patients to be in control of their treatment schedule with access to a team of health coaches., July 2020: Medtronic PLC and Tandem Diabetes Care Inc. announced that they entered into a non-exclusive patent cross-license agreement for certain technologies in the field of diabetes.. Key drivers for this market are: Rising prevalence of diabetes

Increased awareness about diabetes management. Potential restraints include: STRINGENT REGULATORY POLICIES FOR THE APPROVAL OF 3D PRINTING MEDICAL DEVICES 33, . LACK OF SKILLED PROFESSIONALS 33. Notable trends are: Growing Ageing Population to Boost Market Growth.

The North American blood glucose monitoring market, valued at $15.51 billion in 2025, is projected to experience robust growth, driven by the increasing prevalence of diabetes and the rising adoption of advanced monitoring technologies. The market's Compound Annual Growth Rate (CAGR) of 13.13% from 2025 to 2033 indicates significant expansion. This growth is fueled by several key factors: the aging population, increasing awareness of diabetes management, technological advancements in continuous glucose monitoring (CGM) systems offering improved accuracy and convenience, and the growing preference for self-monitoring among individuals with diabetes. The market is segmented by device type (self-monitoring blood glucose devices – including glucometers, test strips, and lancets – and continuous glucose monitoring devices – including sensors and durables) and end-user (hospitals/clinics and home/personal use). The United States constitutes the largest segment, reflecting its higher prevalence of diabetes and greater healthcare expenditure. However, Canada and the Rest of North America also contribute significantly to the overall market size, exhibiting growth driven by similar factors albeit at potentially slightly slower rates due to varying healthcare infrastructure and access. Competition within the market is intense, with major players like Abbott Diabetes Care, Roche, Johnson & Johnson, Dexcom, and Medtronic leading the innovation and market share. Challenges to market growth include the cost of advanced technologies like CGMs, potential inaccuracies with certain devices, and the need for ongoing education and patient compliance to ensure effective diabetes management. The continued expansion of the North American blood glucose monitoring market is anticipated to be influenced by several future trends. These include the development of increasingly sophisticated and integrated CGM systems with improved data analytics capabilities for personalized diabetes management. Furthermore, the rise of telehealth and remote patient monitoring will play a pivotal role in enhancing access to care and improving diabetes management outcomes. The market will likely witness an increased focus on user-friendly devices and mobile applications, facilitating better adherence to treatment regimens. The expansion of coverage by insurance providers for CGM systems will also play a significant role in accelerating market penetration. However, regulatory hurdles related to the approval and reimbursement of new technologies and the potential for market saturation in certain segments could present challenges to sustained growth. Recent developments include: March 2023: Modified Abbott CGM sensors scored FDA nod for use in automated insulin delivery systems., December 2022: Dexcom, a company that manufactures continuous glucose monitors (CGMs) for blood sugar management, announced the FDA approval for their next-generation product, the Dexcom G7 CGM. The G7 is approved for people with all types of diabetes from ages two years and older.. Notable trends are: Continuous Glucose Monitoring Holds Highest Market Share in the North American Blood Glucose Monitoring Market..

The size of the America Blood Glucose Monitoring Market was valued at USD 0.15 Billion in 2023 and is projected to reach USD 2.10 Billion by 2032, with an expected CAGR of 45.80% during the forecast period. Recent developments include: February 2023: Afon has again teased its non-invasive glucose monitor in February 2023, this time with a rendered image of the sensor alongside adapted wearables and connected devices. In order to obtain blood samples for measurement, millions of diabetics must prick their digits with lancets up to ten times per day, resulting in tissue scarring and discomfort. The Afon Blood Glucose Sensor promises to be a painless and non-invasive alternative method. The production of the first widely approved fully non-invasive continuous glucose monitor (CGM) appears to be highly competitive, but it is crucial for any company involved in this type of development to ensure that their product is both safe and accurate, as it could provide potentially life-saving data to millions of users in the future., February 2023: Zoetis has announced the United States release of the AlphaTrak 3 blood glucose monitoring system for diabetic cats and canines in February 2023. This model improves upon the original AlphaTrak by incorporating a new mobile app that enables seamless, simplified communication and sharing of a pet's glucose data and additional information in real-time with the veterinary practice for enhanced diabetic pet care. The innovative new AlphaTrak 3 blood glucose monitoring system provides veterinarians with accurate data to confidently administer optimal medical treatment.. Potential restraints include: HIGH COST ASSOCIATED WITH THE APPLICATION OF RESPIRATORY THERAPEUTIC DEVICES AND TECHNOLOGY.